| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | April 3, 2025 5:00 P.M. |
| Form: | S-3 | ||||||
| |||||||
Save time and jump to the most important pieces.
4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)
4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)
4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)
8-K - LIPELLA PHARMACEUTICALS INC. (0001347242) (Filer)
8-K - LIPELLA PHARMACEUTICALS INC. (0001347242) (Filer)
8-K - LIPELLA PHARMACEUTICALS INC. (0001347242) (Filer)
4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)
4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)
SC 13G/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)
SC 13G/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)
SC 13D/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)
Joint meeting to be held in Las Vegas, May 14-17 Presentation will be delivered by Dr. Alessandro Villa of Miami Cancer Institute Topline study results demonstrate clinically meaningful improvements in OLP Visible lesion resolution during treatment; return toward baseline post-dosing supports localized activity PITTSBURGH, April 23, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella," "we," "our," or the "Company"), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet needs, today announced that its abstract on LP-10 for the treatment of Oral Lichen Planus (OLP) has been accepted for podium presentation at
Second Cohort Results Highlight Efficacy Across All Key Measures and Reinforce Safety of Twice-Daily Oral Rinse Phase 2a Study Now Fully Enrolled Across All Three Dose Cohorts Advancing Toward Phase 2b IND Submission and Broader Regulatory Engagement PITTSBURGH, April 22, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella," "our," "us," or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet needs, today announced positive topline results from the second cohort (0.50 mg) of its Phase 2a multicenter, dose-ranging trial evaluating LP-310, a liposomal-tacrolimus oral rinse formulation of
PITTSBURGH, April 08, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on developing innovative therapies for unmet medical needs, today announced the completion of enrollment in its Phase 2a multicenter, dose-ranging trial evaluating LP-310, a liposomal tacrolimus oral rinse for the treatment of oral lichen planus (OLP). The Phase 2a trial has now fully enrolled participants across all three dose cohorts (0.25 mg, 0.50 mg and 1.0 mg of tacrolimus) at seven U.S. study sites. Topline results from the final cohort (1.0 mg) remain on track for the second quarter of 2025 and will represent the most